Amit X Garg1, P J Devereaux2, Andrew Hill2, Manish Sood2, Bharat Aggarwal2, Luc Dubois2, Swapnil Hiremath2, Randolph Guzman2, Vikram Iyer2, Matthew James2, Eric McArthur2, Louise Moist2, George Ouellet2, Chirag R Parikh2, Virginia Schumann2, Sumit Sharan2, Heather Thiessen-Philbrook2, Sheldon Tobe2, Ron Wald2, Michael Walsh2, Matthew Weir2, Neesh Pannu2. 1. Departments of Medicine (Garg, McArthur, Moist, Schumann, Thiessen-Philbrook, Weir), of Epidemiology and Bio-statistics (Garg, Dubois, Moist, Weir) and of Surgery (Dubois), Western University, London, Ont.; Departments of Health Research Methods, Evidence, and Impact (Devereaux, Walsh), of Medicine (Devereaux, Walsh) and of Surgery (Iyer), McMaster University, Hamilton, Ont.; Departments of Surgery (Hill) and of Medicine (Sood, Hiremath), University of Ottawa, Ottawa, Ont.; Department of Experimental Therapeutics, Cancer Medicine and Immunology (Aggarwal), The University of Texas MD Anderson Cancer Center, Houston, Tex.; Department of Surgery (Guzman), University of Manitoba, Winnipeg, Man.; Department of Medicine (James), University of Calgary, Calgary, Alta.; Faculté de médecine (Ouellet), Université de Montréal, Montréal, Que.; Program of Applied Translational Research, Department of Medicine (Parikh), and Section of Nephrology (Parikh), Yale University School of Medicine, New Haven, Conn.; Department of Anesthesia (Sharan), Laurentian University, Sudbury, Ont.; Department of Medicine (Tobe, Wald), University of Toronto, Toronto, Ont.; Department of Medicine (Pannu), University of Alberta, Edmonton, Alta. amit.garg@lhsc.on.ca. 2. Departments of Medicine (Garg, McArthur, Moist, Schumann, Thiessen-Philbrook, Weir), of Epidemiology and Bio-statistics (Garg, Dubois, Moist, Weir) and of Surgery (Dubois), Western University, London, Ont.; Departments of Health Research Methods, Evidence, and Impact (Devereaux, Walsh), of Medicine (Devereaux, Walsh) and of Surgery (Iyer), McMaster University, Hamilton, Ont.; Departments of Surgery (Hill) and of Medicine (Sood, Hiremath), University of Ottawa, Ottawa, Ont.; Department of Experimental Therapeutics, Cancer Medicine and Immunology (Aggarwal), The University of Texas MD Anderson Cancer Center, Houston, Tex.; Department of Surgery (Guzman), University of Manitoba, Winnipeg, Man.; Department of Medicine (James), University of Calgary, Calgary, Alta.; Faculté de médecine (Ouellet), Université de Montréal, Montréal, Que.; Program of Applied Translational Research, Department of Medicine (Parikh), and Section of Nephrology (Parikh), Yale University School of Medicine, New Haven, Conn.; Department of Anesthesia (Sharan), Laurentian University, Sudbury, Ont.; Department of Medicine (Tobe, Wald), University of Toronto, Toronto, Ont.; Department of Medicine (Pannu), University of Alberta, Edmonton, Alta.
Abstract
BACKGROUND: Curcumin, a popular herbal supplement from the plant turmeric, has prevented ischemic reperfusion and toxin-induced injury in many animal studies and a single-centre randomized human trial. We sought to test whether perioperative oral curcumin (compared with placebo) affects the inflammatory response and risk of postrepair complicationsafter elective abdominal aortic aneurysm repair in humans. METHODS: We conducted a parallel-group, randomized, placebo-controlled trial of patients from 10 hospitals in Canada who were scheduled to undergo elective repair of an unruptured abdominal aortic aneurysm (November 2011 to November 2014). Patients in the treatment group received perioperative oral curcumin (2000-mg doses 8 times over 4 d). Patients, health care providers and local research staff were unaware of the treatment assignment. The primary outcomes were median concentrations of 4 bio markers indicating injury and inflammation (postoperative urine interleukin-18 and perioperative rise in serum creatinine, plasma N-terminal pro-B-type natriuretic peptide and plasma high-sensitivity C-reactive protein). RESULTS: Baseline characteristics were similar in the 2 groups (606 patients overall; median age 76 yr). More than 85% of patients in each group took more than 80% of their scheduled capsules. Neither curcumin nor placebo significantly affected any of the 4 biomarkers (p > 0.05 for all comparisons). Regarding the secondary outcomes, there was a higher risk of acute kidney injury with curcumin than with placebo (17% v. 10%, p = 0.01), but no between-group difference in the median length of hospital stay (5 v. 5 days, p > 0.9) or the risk of clinical events (9% v. 9%, p = 0.9). INTERPRETATION: Curcumin had no beneficial effects when used in elective abdominal aortic aneurysm repair. These findings emphasize the importance of testing turmeric and curcumin before espousing their health benefits, as is currently done in the popular media. TRIAL REGISTRATION: ClinicalTrials.gov, no. NCT01225094.
RCT Entities:
BACKGROUND:Curcumin, a popular herbal supplement from the plant turmeric, has prevented ischemic reperfusion and toxin-induced injury in many animal studies and a single-centre randomized human trial. We sought to test whether perioperative oral curcumin (compared with placebo) affects the inflammatory response and risk of postrepair complications after elective abdominal aortic aneurysm repair in humans. METHODS: We conducted a parallel-group, randomized, placebo-controlled trial of patients from 10 hospitals in Canada who were scheduled to undergo elective repair of an unruptured abdominal aortic aneurysm (November 2011 to November 2014). Patients in the treatment group received perioperative oral curcumin (2000-mg doses 8 times over 4 d). Patients, health care providers and local research staff were unaware of the treatment assignment. The primary outcomes were median concentrations of 4 bio markers indicating injury and inflammation (postoperative urine interleukin-18 and perioperative rise in serum creatinine, plasma N-terminal pro-B-type natriuretic peptide and plasma high-sensitivity C-reactive protein). RESULTS: Baseline characteristics were similar in the 2 groups (606 patients overall; median age 76 yr). More than 85% of patients in each group took more than 80% of their scheduled capsules. Neither curcumin nor placebo significantly affected any of the 4 biomarkers (p > 0.05 for all comparisons). Regarding the secondary outcomes, there was a higher risk of acute kidney injury with curcumin than with placebo (17% v. 10%, p = 0.01), but no between-group difference in the median length of hospital stay (5 v. 5 days, p > 0.9) or the risk of clinical events (9% v. 9%, p = 0.9). INTERPRETATION:Curcumin had no beneficial effects when used in elective abdominal aortic aneurysm repair. These findings emphasize the importance of testing turmeric and curcumin before espousing their health benefits, as is currently done in the popular media. TRIAL REGISTRATION: ClinicalTrials.gov, no. NCT01225094.
Authors: Chirag R Parikh; Steven G Coca; Heather Thiessen-Philbrook; Michael G Shlipak; Jay L Koyner; Zhu Wang; Charles L Edelstein; Prasad Devarajan; Uptal D Patel; Michael Zappitelli; Catherine D Krawczeski; Cary S Passik; Madhav Swaminathan; Amit X Garg Journal: J Am Soc Nephrol Date: 2011-08-11 Impact factor: 10.121
Authors: Reitze N Rodseth; Bruce M Biccard; Yannick Le Manach; Daniel I Sessler; Giovana A Lurati Buse; Lehana Thabane; Robert C Schutt; Daniel Bolliger; Lucio Cagini; Daniela Cardinale; Carol P W Chong; Rong Chu; Miłosław Cnotliwy; Salvatore Di Somma; René Fahrner; Wen Kwang Lim; Elisabeth Mahla; Ramaswamy Manikandan; Francesco Puma; Wook B Pyun; Milan Radović; Sriram Rajagopalan; Stuart Suttie; Thuvaraha Vanniyasingam; William J van Gaal; Marek Waliszek; P J Devereaux Journal: J Am Coll Cardiol Date: 2013-09-26 Impact factor: 24.094
Authors: Lisa M Curtis; James George; Volker Vallon; Stephen Barnes; Victor Darley-Usmar; Sucheta Vaingankar; Gary R Cutter; Orlando M Gutierrez; Michael Seifert; Joachim H Ix; Ravindra L Mehta; Paul W Sanders; Anupam Agarwal Journal: Am J Physiol Renal Physiol Date: 2021-03-29